Cannabis and Amphetamine-type Stimulant-induced Psychoses: A Systematic Overview
Fares Alharbi, Nady el‐Guebaly
Addictive Disorders & Their Treatment July 4, 2016 DOI: 10.1097/adt.0000000000000086 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Peer reviewed |
|---|---|
| Topics | Cannabis |
| Citations | 9 |
| Key findings | The authors report numerous differences between cannabis and amphetamine-type stimulants in source, neurobiological processes, urine screening, average latency before psychosis, clinical features relative to schizophrenia, and risks of psychosis and schizophrenia with drug use. They note that few studies directly compare the two substances, and argue that such comparisons could further illuminate how psychotic features develop. |
Abstract
Background: The recent escalation of cannabis and amphetamine-type stimulant use throughout the world and its association with psychotic symptoms in users has fuelled special concerns.
Objective: This review will focus on cannabis and amphetamine-type stimulant because of their high prevalence and will try to differentiate and compare their associated psychotic features.
Method: A systematic literature search was conducted from 1980 to 2015 in the following databases: MEDLINE, PsycINFO, and PubMed. Articles were included if they were highlighting substance-induced psychoses, with particular emphasis on stimulants/amphetamine/methamphetamine and cannabis/marijuana-induced psychoses, schizophrenia-spectrum disorder, or schizophrenia.
Results: There are many differences between these 2 substances regarding source, neurobiological processes, urine screening test, average latency periods before developing psychosis, clinical features as compared with schizophrenia, risk of using drugs and developing psychosis, and drug use and development of schizophrenia.
Conclusions: Our search elicited many studies of 1 substance and its association with psychosis but few comparative studies of this association across substances. Yet, in our opinion these comparisons could shed further insight into the development of psychotic features.
Comparable studies
Other systematic reviews and meta-analyses on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Effects of cannabis use on outcomes of psychotic disorders: systematic review People with psychotic disorders, as examined in 13 longitudinal studies | 2008 | Systematic review | |
| The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... | 2010 | Meta-analysis and cross-sectional observational study | n = 700 |
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review | 2020 | Systematic review | |
| Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies | 2009 | Systematic review | |
| Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia | 2016 | Systematic review |
Citations in the library
Cites 11
- Causal association between cannabis and psychosis: examination of the evidence The British Journal of Psychiatry January 30, 2004
- Effects of cannabis use on outcomes of psychotic disorders: systematic review The British Journal of Psychiatry October 31, 2008
- Familial Predisposition for Psychiatric Disorder Archives of General Psychiatry November 3, 2008
- How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophrenia Bulletin March 2015
- Are Cannabis Use Disorders Associated with an Earlier Age at Onset of Psychosis? A Study in First Episode Schizophrenia Schizophrenia Research May 14, 2010
and 6 more in the library